Publicacións en colaboración con investigadores/as de Hospital Universitario Son Espases (26)

2024

  1. Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients

    Allergy: European Journal of Allergy and Clinical Immunology

2023

  1. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 7, pp. 1934-1948

  2. Factors associated with suboptimal response to monoclonal antibodies in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology

  3. First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

    Journal of Investigational Allergology and Clinical Immunology

  4. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2732-2747

  5. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study

    Chest, Vol. 164, Núm. 4, pp. 837-845

  6. Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population

    Archivos de Bronconeumologia, Vol. 59, Núm. 12, pp. 842-845

2022

  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 5, pp. 1202-1216.e23

  2. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

    Journal of Asthma and Allergy, Vol. 15, pp. 63-78

2021

  1. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 7, pp. 2725-2731

  2. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

    Chest

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. Hospital epidemics tracker (hepitracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers

    JMIR Public Health and Surveillance, Vol. 6, Núm. 3

  3. International severe asthma registry (ISAR): Protocol for a global registry

    BMC Medical Research Methodology, Vol. 20, Núm. 1

  4. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab

    Allergy: European Journal of Allergy and Clinical Immunology

2019

  1. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 2, pp. 578-588.e2

  2. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2

  3. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study

    Respiratory Medicine, Vol. 151, pp. 49-54

2018

  1. Accuracy of a New Algorithm to Identify Asthma–COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease

    Archivos de Bronconeumologia, Vol. 54, Núm. 4, pp. 198-204

  2. Asthma–COPD overlap: identification and optimal treatment

    Therapeutic Advances in Respiratory Disease, Vol. 12